Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Introduction
00:00 • 3min
The E-Cog 1910 Trial
03:18 • 4min
The Effects of Blint on Survival in MRD Positive Patients
07:23 • 3min
The E2993 Study on Morphologic Remission
09:54 • 5min
The UCal 14 Study: A Well Thought Out Regimen for All Chemotherapy
15:16 • 3min
The Long Immortal Time Bias in the Study
18:20 • 6min
The Elephant in the Room: Does Blend a Tumumab Really Improve Survival?
23:56 • 3min
The Importance of Randomization in Tumor MAB
27:20 • 3min
The Importance of Accelerated Approvals in the Treatment of MRT-positive Patients
30:49 • 2min
The Effects of Tumumab on the Survival of MRT-Negative Patients
33:17 • 5min
The Challenge of Speculating on Random Subgroups
37:55 • 2min
The Role of BLIN in the Treatment of MRT Negative Patients
39:34 • 3min
The Importance of Pediatric Inspired Therapy in the Treatment of Hepatic Steatosis
42:24 • 3min
The Importance of BFM in Adult Patients
45:32 • 3min
BLIN at Tumumab: The Best Chemotherapy for Hyper C VAD
48:28 • 2min
The Role of MRD Levels in Clonosceke Therapy
49:59 • 5min
The Importance of Waiting Longer for MRD Treatment
55:04 • 2min
The Practice of All for Adolescent Young Adults
57:13 • 3min
The Cost of Pediatric Inspired Therapy
01:00:27 • 2min
Linetumabha and the Disparities in Care
01:02:43 • 5min